Patients & Families
PATIENTS AND FAMILIES ARE AT THE HEART OF WHAT WE DO
At Imbria, our work is guided by the people living with serious cardiovascular diseases like nHCM and HFpEF and those who support them every day.
We are committed to advancing new treatment options while honoring the experiences, needs, and hopes of patients and their families
Non-obstructive Hypertropic Cardiomyopathy (nHCM)
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, characterized by the abnormal thickening of the heart muscle, which can lead to various complications. HCM is most often diagnosed in middle age, and symptoms can vary widely. In non-obstructive HCM (nHCM), the heart muscle becomes abnormally thickened, impairing the blood flow out of the heart, leading to the heart muscle working harder to pump blood to meet the body’s metabolic demands.
Patients with nHCM experience a high burden of heart failure symptoms such as shortness of breath, fatigue, and irregular heart rhythms. Despite the significant impact of this condition, there are no approved treatments available.
Heart Failure with Preserved Ejection Fraction (HFpEF)
HFpEF is a type of heart failure where the heart contracts normally but struggles to relax and fill properly, leading to symptoms like breathlessness, fluid retention, and reduced exercise capacity.
It is one of the most common and challenging forms of heart failure, often affecting older adults and those with other health conditions.
EXPANDED ACCESS AT IMBRIA
Imbria is committed to developing innovative therapies for people living with serious cardiovascular diseases. At this time, access to our investigational medicines is primarily through participation in clinical trials, which help us ensure treatments are studied in a safe, controlled, and scientifically rigorous way.
We know that patients and families often have questions about other ways to access these medicines. View our policy on expanded access.